Free Trial
NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

PMV Pharmaceuticals logo
$1.42 -0.03 (-1.74%)
As of 02:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About PMV Pharmaceuticals Stock (NASDAQ:PMVP)

Advanced

Key Stats

Today's Range
$1.40
$1.49
50-Day Range
$1.14
$1.60
52-Week Range
$0.81
$1.84
Volume
267,252 shs
Average Volume
492,364 shs
Market Capitalization
$74.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Hold

Company Overview

PMV Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

PMVP MarketRank™: 

PMV Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 460th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PMV Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    PMV Pharmaceuticals has a consensus price target of $5.50, representing about 288.7% upside from its current price of $1.42.

  • Amount of Analyst Coverage

    PMV Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about PMV Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.06) to ($1.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PMV Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PMV Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PMV Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about PMV Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.43% of the outstanding shares of PMV Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    PMV Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PMV Pharmaceuticals has recently decreased by 5.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PMV Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    PMV Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.43% of the outstanding shares of PMV Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    PMV Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PMV Pharmaceuticals has recently decreased by 5.98%, indicating that investor sentiment is improving significantly.
  • Search Interest

    3 people have searched for PMVP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PMV Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $900,000.00 in company stock.

  • Percentage Held by Insiders

    Only 7.60% of the stock of PMV Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about PMV Pharmaceuticals' insider trading history.
Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PMVP Stock News Headlines

October 2025 Market Crash?
Wall Street Legend Names #1 Stock [not NVDA] The greatest quantitative mind on Wall Street just revealed his #1 A.I. pick, 100% free.tc pixel
Pmv Pharmaceuticals Inc (PMVP) - Investing.com
See More Headlines

PMVP Stock Analysis - Frequently Asked Questions

PMV Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, PMVP shares have decreased by 6.3% and is now trading at $1.4150.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.02.

PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC).

Company Calendar

Last Earnings
8/07/2025
Today
10/06/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMVP
CIK
1699382
Fax
N/A
Employees
50
Year Founded
2013

Price Target and Rating

High Price Target
$6.00
Low Price Target
$5.00
Potential Upside/Downside
+272.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$58.71 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-47.94%
Return on Assets
-43.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.52
Quick Ratio
12.52

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.40 per share
Price / Book
0.43

Miscellaneous

Outstanding Shares
52,990,000
Free Float
48,964,000
Market Cap
$78.16 million
Optionable
Optionable
Beta
1.51

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PMVP) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners